Kodiak Sciences Inc
KOD
Positions held
Your positionsKOD isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Kodiak Sciences operates in the biotechnology sector, which is known for its potential for high returns due to innovation and unmet medical needs.
- The company's market cap is approximately $5.8 billion, indicating significant investor interest and potential for growth.
- Kodiak Sciences has a strong buy recommendation with a score of 62.00, reflecting positive market sentiment and technical indicators.
- The company has reported zero revenue for multiple quarters, which raises concerns about its ability to generate income in the near future.
- Kodiak Sciences has a negative profit margin of 0.0 and a net income loss of -260.491 million in 2023, highlighting ongoing financial struggles.
- The debt-to-equity ratio stands at 86.349, suggesting a high level of debt relative to equity, which could pose risks for investors.
Fundamentals
| Market cap | $5.92B | Enterprise value | $5.84B | Trailing P/E | — | Forward P/E | -27.44 |
| PEG | — | Price / book | 96.78 | Beta | 2.04 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -3.7% | ROA | -60.4% | Debt / equity | 0.86 |
| Current ratio | 2.49 | Free cash flow | -$58.39M | Analyst recommendation | strong_buy | Mean target | $116.67 |
| 52w high | $104.00 | 52w low | $10.94 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$65.6M | -$58.2M | -$56.7M | -$61.5M | -$54.3M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$66.8M | -$59.8M | -$57.5M | -$62.4M | -$55.5M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$230M | -$176M | -$260M | -$334M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$234M | -$187M | -$277M | -$341M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update
2026-10-08 · Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News
2026-10-07 · Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
2026-10-06 · Kodiak Sciences Stock Pick of the Week at Smart Insider Following Insider Share Purchase
2026-10-02 · Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
2026-10-02 · This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
2026-10-01 · Kodiak Sciences More Than Doubles on Eye Disease Trial Results
2026-09-30 · A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
2026-09-29 · This is the top biotech stock pick from B Riley Securities
2026-09-29 · KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
2026-09-29 · What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?
2026-09-29 · Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Price (daily)
Full chart · RSI · MACD · patterns